| 
July
16, 2003 Issue 164
This
Week...
I was at the recent Children With Diabetes Friends for Life
2003 Annual Conference at Disney's Coronado Springs Resort.
Jeff and Laura and all the rest of the volunteer staff do
a fabulous job of making the over 800 families who attended
feel right at home. To learn more about what went on click
here.
Leonard Lipson, M.A., Psychology joins
us for part 5 of his series The
Urge with A Real Persons’ Experience. If you want
to learn the inside “psyche” on your patients
thought process of their diabetes, you need to read all
5 parts.
With only 3 weeks to go until AADE we want to remind you
that we will be in at Booth #1333, between
Roche, Aventis and Takeda. Please stop by to see our special
presentations. Dr. Fred Pescatore and Kristina
Sandstedt will be there, and so will Dr.
Paul Chous. Stay tuned for exact times and dates.
It’s amazing to see the difference in the same foods
at different restaurants. Check out the Cole Slaw and Hush
Puppies at this weeks favorite “fast foods”
locations. Long John
Silvers and Captain D’s
Paul Chous, M.A.,Doctor of Optometry and
Type 1 diabetic since 1968, brings to our attention the
manifestations of Diabetic
Eye Disease Affecting The Transparent Ocular Media
This week’s overview:
Item#6: Testosterone
Inversely Associated With Atherosclerosis in Diabetic Men
Item:#12: Diabetes
More Common in Snorers, Problem Sleepers
Item #13: Intensive
Glycemic Control Pays Interest Before and After Retirement
Check out this weeks “Test Your Knowledge”
question. Click Here
Dave
Joffe, Editor-in-Chief, CDE, FACA
Consider
making Diabetes in Control Your home page.
NewsFlash:
Late-Breaking Clinical Trial Results of the
Carvedilol Vs. Metoprolol European COMET Trial Carvedilol
is Associated With A Significant Survival Benefit Over Metoprolol
See Item#9
Good News: FDA announced the final rule
requiring food manufacturers to list trans fat on Nutrition
Facts labels. Bad News: The labels are not required until
2006.
1. New Treatment For ED Effective for Up to 36 Hours in
Patients*
Click Here
2. Renal Insufficiency Without Albuminuria, Retinopathy
Common in Type 2 Diabetics
Click Here
3. Diabetes Increases Risk of Idiopathic Pulmonary Fibrosis
Click Here
4. 30 Minutes of Exercise Reverses Pre-Diabetes*
Click Here
5. Insulin Pump Therapy Lowers HbA1c Than More Insulin Glargine
Click Here
6. Testosterone Inversely Associated With Atherosclerosis
in Diabetic Men
Click Here
7. Glargine Vs. NPH In Combo With Oral Treatment In Type
2’s
Click Here
8. Rosiglitazone Improves Insulin Sensitivity, Glucose Control
and Inflammation
Click Here
9 Late-Breaking Clinical Trial Results: Carvedilol Vs. Metoprolol
European COMET Trial*
Click Here
10. 'Pre-diabetes' Raises Risk of Dying from Cancer*
Click Here
11. Fish Insulin Discovery A Breakthrough In Diabetes Treatment
Click Here
12. Diabetes More Common in Snorers, Problem Sleepers
Click Here
13. Intensive Glycemic Control Pays Interest Before and
After Retirement
Click Here
14. Drug for Treating Type-2 Diabetes May Limit Heart Disease
Risk
Click Here
15. Obesity Increases Risk for Death from Cancer
Click Here
Product
Update
 A1cNow
is Now Over the Counter-No Prescription Needed!
Let
your Patients Check Their Own A1c Levels. It will motivate
to better control.
www.a1cnow.net
QUOTE OF THE WEEK
“Yesterday
is not ours to recover, but tomorrow is ours to win or to
lose.”
Lyndon B. Johnson
Prescription
Drug Plan Faces Tests
Insurers' Participation Uncertain, Experts
Say
Congress's dramatic pre-dawn votes
on Friday to add prescription drug benefits to Medicare
were a political milestone, authorizing the biggest
expansion of the program since its birth. But health
policy analysts say that, even if the House and the
Senate are able to resolve differences between their
bills, it is far from certain the plan would work.
The drug coverage envisioned by Congress and the White
House relies on two kinds of private insurance methods:
separate policies solely for drugs, something that
does not currently exist, and preferred-provider networks,
a health plan that is common among younger people
but includes few Medicare patients. Read
More...>
|
|
Brings
use part 5 of his series 
Sleep
Sentry® Newly FDA approved monitor / alarm for the
treatment of nighttime hypoglycemia. 
Melissa
Diane Smith
Evan
D. Rosen, M.D., Ph.D 
New
Treatment For ED Effective for Up to 36 Hours in Patients* 
Paul
Chous, 
The goal of this educational activity is to address the
important role of insulin delivery systems in helping patients meet their
individual therapeutic goals. 
Dr.
Eric Freedland's
